News
Hereditary transthyretin (hATTR) amyloidosis, also known as variant ATTR (ATTRv) amyloidosis, is a rare disease affecting about 50,000 people worldwide. It's caused…
Published: Oct 09, 2023
- FDA Cites Insufficient Evidence of Clinical Meaningfulness -
- No Clinical Safety, Study Conduct, Drug Quality or Manufacturing…
- Cardiovascular and Renal Drugs Advisory Committee Voted 9:3 That the Benefits of Patisiran Outweigh its Risks for the Treatment of the Cardiomyopathy of ATTR…
Kochi: India's first center of excellence for the evaluation and treatment of patients with suspected or established amyloidosis was launched today at Amrita…
Nexcella, Inc., a biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced…
Register for the ATTR Patient Summit April 28 - 30, 2023
HAC/TAC is proud to present the first-ever Canadian-specific ATTR Patient Summit, an…
The FDA's Center for Biologics Evaluation and Research (CBER) Office of Therapeutic Products (OTP) is hosting a public virtual workshop on Thursday, April 13, from…
Support Group Contact:
John Mathison: John@AmyloidosisSupport.org
Muriel: Muriel@AmyloidosisSupport.org
866-404-7539 (Toll-Free)
Meeting Date:
March 4, 2023…
Support Group Contact:
Kay Rowley: Kay@AmyloidosisSupport.org, 866-404-7539 (Toll-Free).
Meeting Date:
May 20, 2023
Meeting Time:
9-11am
Meeting Location Address:…
Calling all amyloidosis patients! In celebration of Amyloidosis Awareness Month, Mackenzie's Mission is creating a new FACES of Amyloidosis video. PLEASE CONSIDER…